Thrombotargets is the biotech company that develops new medicines (recombinant DNA, molecular biology and small molecule drug technologies) for superficial thrombosis and other kinds of coagulation diseases.
The potent hemostatic effects of TT-103MH have also been observed in samples from patients with congenital platelet disorders, such as the Bernard-Soulier Syndrome and Glanzmann's Disease. Thrombotargets is developing the first antihemorrhagic drug useful for treating topically all kinds of bleeding. Know more about us.
Thrombotargets is developing new drug for hemostasis, atherosclerosis, aging and thrombosis. Know the revolutionary antihemorrhagic agents for all kind of bleeding treatments.
TT-103MH is a new recombinant protein developed for use in the treatment of non-life threatening mild-to-severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliacs. It has been observed to prevent death in a lethal model of hemophilia in mice; TT-103MH also reduced blood coagulation time up to 90% in ex vivo studies using hemophiliac blood.
|
